Topiroxostat

A xanthine oxidase inhibitor used to treat hyperuricemia

Topiroxostat
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Topiroxostat is a medication used primarily for the treatment of hyperuricemia in patients with gout. It functions as a xanthine oxidase inhibitor, which helps to reduce the production of uric acid in the body.

Mechanism of Action

Topiroxostat works by inhibiting the activity of xanthine oxidase, an enzyme responsible for the conversion of hypoxanthine to xanthine and subsequently to uric acid. By blocking this enzyme, topiroxostat decreases the production of uric acid, thereby lowering its levels in the blood.

Clinical Use

Topiroxostat is prescribed for patients with hyperuricemia associated with gout. It is particularly useful for individuals who have not responded adequately to other treatments or who have contraindications to other medications.

Side Effects

Common side effects of topiroxostat include liver function test abnormalities, nausea, and rash. Patients are advised to undergo regular monitoring of liver function during treatment.

Pharmacokinetics

Topiroxostat is administered orally and is absorbed in the gastrointestinal tract. It is metabolized in the liver and excreted primarily through the kidneys.

Related Pages

• Gout
• Hyperuricemia
• Xanthine oxidase inhibitor

References

• Kamatani, N., et al. (2014). "Efficacy and safety of topiroxostat, a novel xanthine oxidase inhibitor, in Japanese hyperuricemic patients with or without gout: a 12-week, multicenter, double-blind, placebo-controlled, parallel-group study." Clinical Therapeutics, 36(10), 1562-1576.
• Yamanaka, H., et al. (2017). "Topiroxostat for the treatment of hyperuricemia in patients with gout: a phase 3, multicenter, randomized, double-blind, placebo-controlled study." Arthritis Research & Therapy, 19(1), 1-10.